<p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近向美國證券交易委員會提交的 13F 表格中披露，第二季度其在 Praxis Precision Medicines, Inc. (NASDAQ:PRAX - 免費報告) 的持股減少了 18.3%。該基金在季度內出售了 4,901 股後，持有該公司 21,892 股股票。OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近的報告期末持有約 0.10% 的 Praxis Precision Medicines，價值 921,000 美元。</p>
<p>其他一些機構投資者最近也增加或減少了在 PRAX 的持股。HighVista Strategies LLC 在第二季度將其在 Praxis Precision Medicines 的持股增加了 71.3%。HighVista Strategies LLC 目前持有 67,288 股該公司的股票，價值 2,829,000 美元，此前在上個季度又購買了 28,002 股。Stempoint Capital LP 在第二季度購買了 Praxis Precision Medicines 的新股份，價值 1,356,000 美元。B Group Inc. 在第二季度將其在 Praxis Precision Medicines 的持股增加了 84.2%。B Group Inc. 目前持有 35,000 股該公司的股票，價值 1,472,000 美元，此前在該期間又收購了 16,000 股。Vivo Capital LLC 在第二季度收購了 Praxis Precision Medicines 的新股份，估計價值約為 7,048,000 美元。最後，Maven Securities LTD 在第二季度購買了 Praxis Precision Medicines 的新股份，估計價值約為 210,000 美元。對沖基金和其他機構投資者持有該公司 67.84% 的股票。</p>
<h2>Praxis Precision Medicines 的內部交易</h2>
<p>在相關消息中，首席法律顧問 Alex Nemiroff 於 11 月 20 日星期四出售了 25,130 股該公司的股票。股票以平均價格 193.09 美元出售，總交易額為 4,852,351.70 美元。交易完成後，首席法律顧問直接持有該公司 20,832 股股票，價值 4,022,450.88 美元。此交易代表其持股減少了 54.68%。該出售在向美國證券交易委員會的法律文件中披露，相關文件可通過此鏈接獲取。此外，內部人士 Lauren Mastrocola 於 11 月 20 日星期四出售了 13,600 股該公司的股票。股票以平均價格 192.08 美元出售，總交易額為 2,612,288.00 美元。出售後，內部人士持有該公司 10,442 股股票，價值 2,005,699.36 美元。此交易代表其持股減少了 56.57%。該出售的披露信息可在美國證券交易委員會的文件中找到。公司內部人士持有該公司 2.70% 的股票。</p>
<h2>分析師評級的升級和降級</h2>
<p>多位股票分析師對該股票發表了評論。Guggenheim 在週二的研究報告中重申了對 Praxis Precision Medicines 的 &#34;買入&#34; 評級，並將目標價格從 540.00 美元上調至 760.00 美元。Truist Financial 在週一將 Praxis Precision Medicines 的目標價格從 360.00 美元提高到 500.00 美元，並給予該公司 &#34;買入&#34; 評級。Weiss Ratings 在週一的研究報告中重申了對 Praxis Precision Medicines 的 &#34;賣出 (e+)&#34; 評級。HC Wainwright 在 12 月 5 日星期五重申了 &#34;買入&#34; 評級，並將目標價格從 258.00 美元上調至 340.00 美元。最後，Chardan Capital 在 11 月 19 日星期三將 Praxis Precision Medicines 的評級上調至 &#34;強力買入&#34;。兩位研究分析師對該股票給予了強力買入評級，十三位給予了買入評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;適度買入&#34;，共識目標價格為 333.00 美元。</p>
<p><strong>閲讀我們關於 Praxis Precision Medicines 的最新股票報告</strong></p>
<h2>Praxis Precision Medicines 股票上漲 2.2%</h2>
<p>NASDAQ PRAX 的股票在週五開盤時為 267.28 美元。該公司的市值為 66.8 億美元，市盈率為 -20.72，貝塔值為 2.95。Praxis Precision Medicines, Inc. 的 52 周低點為 26.70 美元，52 周高點為 278.44 美元。該公司的 50 日移動平均線為 167.50 美元，200 日移動平均線為 88.71 美元。</p>
<p>Praxis Precision Medicines (NASDAQ:PRAX - 獲取免費報告) 最近於 11 月 5 日星期三發佈了季度財報。該公司報告季度每股收益為 ($3.36)，超出市場共識預期的 ($3.45) 0.09 美元。分析師預計 Praxis Precision Medicines, Inc. 在當前財政年度將發佈 -10.22 的每股收益。</p>
<h2>Praxis Precision Medicines 公司簡介</h2>
<p>(免費報告)</p>
<p>Praxis Precision Medicines, Inc. 是一家臨牀階段的生物製藥公司，專注於開發針對中樞神經系統疾病的治療，這些疾病的特徵是神經興奮 - 抑制失衡。該公司正在開發 ulixacaltamide，這是一種 T 型鈣通道的小分子抑制劑，目前正在進行 III 期臨牀試驗，治療原發性震顫；PRAX-562 用於治療患有發育性和癲癇性腦病 (DEE) 的兒童患者；以及 PRAX-628 用於治療局灶性癲癇。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而非 Praxis Precision Medicines</li>
<li>專家股票交易心理學技巧</li>
<li>2026 年應避免的三隻最近被降級的股票</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>芯片熱潮迴歸：三隻有望大幅上漲的股票</li>
<li>投資建築類股票</li>
<li>甲骨文股票遭重創：為何其 AI 管道可能推動 2026 年的反彈</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Praxis Precision Medicines 嗎？</h2>
<p>在考慮投資 Praxis Precision Medicines 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而 Praxis Precision Medicines 並不在名單上。</p>
<p>雖然 Praxis Precision Medicines 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PRAX

<p>OCONNOR，瑞銀資產管理的一個部門，在第二季度減少了對 Praxis Precision Medicines 的持股 18.3%。其他機構投資者也調整了他們的持倉，其中一些增加了他們的股份。內部交易包括公司高管的大量股票出售。分析師的評級各不相同，普遍共識為 “適度買入”，目標價格為 333 美元。Praxis 的股票上漲了 2.2%，市值為 66.8 億美元</p>

<p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) by 18.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 21,892 shares of the company's stock after selling 4,901 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.10% of Praxis Precision Medicines worth $921,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近向美國證券交易委員會提交的 13F 表格中披露，第二季度其在 Praxis Precision Medicines, Inc. (NASDAQ:PRAX - 免費報告) 的持股減少了 18.3%。該基金在季度內出售了 4,901 股後，持有該公司 21,892 股股票。OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC 在最近的報告期末持有約 0.10% 的 Praxis Precision Medicines，價值 921,000 美元。</p>
</div><p>A number of other institutional investors have also recently added to or reduced their stakes in PRAX. HighVista Strategies LLC boosted its stake in Praxis Precision Medicines by 71.3% during the second quarter. HighVista Strategies LLC now owns 67,288 shares of the company's stock worth $2,829,000 after buying an additional 28,002 shares during the last quarter. Stempoint Capital LP purchased a new position in shares of Praxis Precision Medicines during the 2nd quarter worth $1,356,000. B Group Inc. raised its holdings in shares of Praxis Precision Medicines by 84.2% during the 2nd quarter. B Group Inc. now owns 35,000 shares of the company's stock worth $1,472,000 after acquiring an additional 16,000 shares during the period. Vivo Capital LLC acquired a new position in shares of Praxis Precision Medicines during the 2nd quarter valued at about $7,048,000. Finally, Maven Securities LTD purchased a new stake in shares of Praxis Precision Medicines in the second quarter valued at about $210,000. Hedge funds and other institutional investors own 67.84% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者最近也增加或減少了在 PRAX 的持股。HighVista Strategies LLC 在第二季度將其在 Praxis Precision Medicines 的持股增加了 71.3%。HighVista Strategies LLC 目前持有 67,288 股該公司的股票，價值 2,829,000 美元，此前在上個季度又購買了 28,002 股。Stempoint Capital LP 在第二季度購買了 Praxis Precision Medicines 的新股份，價值 1,356,000 美元。B Group Inc. 在第二季度將其在 Praxis Precision Medicines 的持股增加了 84.2%。B Group Inc. 目前持有 35,000 股該公司的股票，價值 1,472,000 美元，此前在該期間又收購了 16,000 股。Vivo Capital LLC 在第二季度收購了 Praxis Precision Medicines 的新股份，估計價值約為 7,048,000 美元。最後，Maven Securities LTD 在第二季度購買了 Praxis Precision Medicines 的新股份，估計價值約為 210,000 美元。對沖基金和其他機構投資者持有該公司 67.84% 的股票。</p>
</div><h2>Insider Transactions at Praxis Precision Medicines</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 的內部交易</h2>
</div><p>In related news, General Counsel Alex Nemiroff sold 25,130 shares of the firm's stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $193.09, for a total transaction of $4,852,351.70. Following the completion of the transaction, the general counsel directly owned 20,832 shares in the company, valued at $4,022,450.88. This trade represents a 54.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Lauren Mastrocola sold 13,600 shares of the business's stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $192.08, for a total transaction of $2,612,288.00. Following the sale, the insider owned 10,442 shares in the company, valued at $2,005,699.36. This trade represents a 56.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 2.70% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，首席法律顧問 Alex Nemiroff 於 11 月 20 日星期四出售了 25,130 股該公司的股票。股票以平均價格 193.09 美元出售，總交易額為 4,852,351.70 美元。交易完成後，首席法律顧問直接持有該公司 20,832 股股票，價值 4,022,450.88 美元。此交易代表其持股減少了 54.68%。該出售在向美國證券交易委員會的法律文件中披露，相關文件可通過此鏈接獲取。此外，內部人士 Lauren Mastrocola 於 11 月 20 日星期四出售了 13,600 股該公司的股票。股票以平均價格 192.08 美元出售，總交易額為 2,612,288.00 美元。出售後，內部人士持有該公司 10,442 股股票，價值 2,005,699.36 美元。此交易代表其持股減少了 56.57%。該出售的披露信息可在美國證券交易委員會的文件中找到。公司內部人士持有該公司 2.70% 的股票。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級的升級和降級</h2>
</div><p>A number of equities analysts have commented on the stock. Guggenheim reaffirmed a &#34;buy&#34; rating and set a $760.00 target price (up from $540.00) on shares of Praxis Precision Medicines in a research note on Tuesday. Truist Financial increased their price target on shares of Praxis Precision Medicines from $360.00 to $500.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Praxis Precision Medicines in a research report on Monday. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $340.00 price objective (up from $258.00) on shares of Praxis Precision Medicines in a report on Friday, December 5th. Finally, Chardan Capital upgraded Praxis Precision Medicines to a &#34;strong-buy&#34; rating in a research report on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $333.00.</p>
<div class="lb-trans"><p>多位股票分析師對該股票發表了評論。Guggenheim 在週二的研究報告中重申了對 Praxis Precision Medicines 的 &#34;買入&#34; 評級，並將目標價格從 540.00 美元上調至 760.00 美元。Truist Financial 在週一將 Praxis Precision Medicines 的目標價格從 360.00 美元提高到 500.00 美元，並給予該公司 &#34;買入&#34; 評級。Weiss Ratings 在週一的研究報告中重申了對 Praxis Precision Medicines 的 &#34;賣出 (e+)&#34; 評級。HC Wainwright 在 12 月 5 日星期五重申了 &#34;買入&#34; 評級，並將目標價格從 258.00 美元上調至 340.00 美元。最後，Chardan Capital 在 11 月 19 日星期三將 Praxis Precision Medicines 的評級上調至 &#34;強力買入&#34;。兩位研究分析師對該股票給予了強力買入評級，十三位給予了買入評級，兩位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的平均評級為 &#34;適度買入&#34;，共識目標價格為 333.00 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Praxis Precision Medicines</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Praxis Precision Medicines 的最新股票報告</strong></p>
</div><h2>Praxis Precision Medicines Stock Up 2.2%</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 股票上漲 2.2%</h2>
</div><p>Shares of NASDAQ PRAX opened at $267.28 on Friday. The firm has a market cap of $6.68 billion, a price-to-earnings ratio of -20.72 and a beta of 2.95. Praxis Precision Medicines, Inc. has a 52-week low of $26.70 and a 52-week high of $278.44. The business's 50 day moving average is $167.50 and its two-hundred day moving average is $88.71.</p>
<div class="lb-trans"><p>NASDAQ PRAX 的股票在週五開盤時為 267.28 美元。該公司的市值為 66.8 億美元，市盈率為 -20.72，貝塔值為 2.95。Praxis Precision Medicines, Inc. 的 52 周低點為 26.70 美元，52 周高點為 278.44 美元。該公司的 50 日移動平均線為 167.50 美元，200 日移動平均線為 88.71 美元。</p>
</div><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($3.36) EPS for the quarter, topping the consensus estimate of ($3.45) by $0.09. Analysts anticipate that Praxis Precision Medicines, Inc. will post -10.22 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Praxis Precision Medicines (NASDAQ:PRAX - 獲取免費報告) 最近於 11 月 5 日星期三發佈了季度財報。該公司報告季度每股收益為 ($3.36)，超出市場共識預期的 ($3.45) 0.09 美元。分析師預計 Praxis Precision Medicines, Inc. 在當前財政年度將發佈 -10.22 的每股收益。</p>
</div><h2>Praxis Precision Medicines Company Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc. 是一家臨牀階段的生物製藥公司，專注於開發針對中樞神經系統疾病的治療，這些疾病的特徵是神經興奮 - 抑制失衡。該公司正在開發 ulixacaltamide，這是一種 T 型鈣通道的小分子抑制劑，目前正在進行 III 期臨牀試驗，治療原發性震顫；PRAX-562 用於治療患有發育性和癲癇性腦病 (DEE) 的兒童患者；以及 PRAX-628 用於治療局灶性癲癇。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>Expert Stock Trading Psychology Tips</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Investing in Construction Stocks</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非 Praxis Precision Medicines</li>
<li>專家股票交易心理學技巧</li>
<li>2026 年應避免的三隻最近被降級的股票</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>芯片熱潮迴歸：三隻有望大幅上漲的股票</li>
<li>投資建築類股票</li>
<li>甲骨文股票遭重創：為何其 AI 管道可能推動 2026 年的反彈</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJBWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PRAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Praxis Precision Medicines 嗎？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Praxis Precision Medicines 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻股票，頂級分析師正在悄悄地向他們的客户推薦在更廣泛的市場注意到之前購買……而 Praxis Precision Medicines 並不在名單上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Praxis Precision Medicines 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

OCONNOR 是瑞銀資產管理美洲有限責任公司的一家獨立業務部門，該部門減少了在 Praxis Precision Medicines, Inc. $PRAX 的股票持倉